Poolbeg Pharma PLC (7JN.F)

0.1550 +0.0170 (+12.32%) 收市：08:23AM CEST

Poolbeg Pharma PLC

Queen Mary BioEnterprises Innovation Ctr
42 New Road
London E1 2AX
United Kingdom
44 20 7183 1499
https://www.poolbegpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Cathal Martin Friel	Executive Chairman of The Board	175.27k	無	1964
Dr. Jeremy Skillington Ph.D.	CEO & Director	422.99k	無	1971
Mr. Ian O'Connell	CFO & Director	276.93k	無	1987
Carol Dalton	Vice President of Investor Relations & Public Relations	無	無	無
Mr. John McEvoy	Senior Vice President & Chief Legal Officer	無	無	無
Mr. David James Allmond	Chief Business Officer	無	無	1970
Mr. Ross Crockett	Group Financial Controller	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

公司管治

截至 無 止，Poolbeg Pharma PLC 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。